Analyst consensus rating
Innate Pharma Analyst Rating: none
Direct answer
Innate Pharma's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.67.
Forecast evidence checked October 17, 2026.
Get free Innate Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.43
- Average price target
- $6.67
- High price target
- $9.00
- Low price target
- $4.00
- Low target gap
- +179.7%
- Target upside
- +366.2%
- High target gap
- +529.4%
- Target range width
- 349.7%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Innate Pharma?
Innate Pharma has a verified none consensus. The same dataset has an average price target of $6.67.
How far are Innate Pharma's low and high targets from the recorded price?
The low target implies +179.7%, while the high target implies +529.4%.
How many analysts are included in Innate Pharma's consensus?
The verified consensus includes 3 analysts.
How is Innate Pharma's target upside or downside calculated?
The average target of $6.67 is divided by the recorded price of $1.43, then one is subtracted to produce +366.2%. This does not guarantee a future return.
When was Innate Pharma's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.